Conditional knockout of the NSD2 gene in mouse intestinal epithelial cells inhibits colorectal cancer progression

Abstract

Background: Nuclear receptor-binding SET domain 2 (NSD2) is a histone methyltransferase, that catalyzes dimethylation of lysine 36 of histone 3 (H3K36me2) and is associated with active transcription of a series of genes. NSD2 is overexpressed in multiple types of solid human tumors and has been proven to be related to unfavorable prognosis in several types of tumors.

Methods: We established a mouse model in which the NSD2 gene was conditionally knocked out in intestinal epithelial cells. We used azoxymethane and dextran sodium sulfate to chemically induce murine colorectal cancer. The development of colorectal tumors were investigated using post-necropsy quantification, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA).

Results: Compared with wild-type (WT) control mice, NSD2^fl/fl-Vil1-Cre mice exhibited significantly decreased tumor numbers, histopathological changes, and cytokine expression in colorectal tumors.

Conclusions: Conditional knockout of NSD2 in intestinal epithelial cells significantly inhibits colorectal cancer progression.

Keywords

colorectal cancer / NSD2 ^fl/fl-Vil1-Cre mice / nuclear receptor-binding SET domain 2

References

[1] Chen R, Chen Y, Zhao W, et al. The role of methyltransferase NSD2 as a potential oncogene in human solid tumors. Onco Targets Ther. 2020;13:6837-6846.

[2] Topchu I, Pangeni RP, Bychkov I, et al. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cell Mol Life Sci. 2022;79(6):285.

[3] Bao ZM, Yao D, Qian X, et al. Activating transcription factor 2 promotes the progression of hepatocellular carcinoma by inducing the activation of the WHSC1-mediated TOP2A/PI3K/AKT axis. Kaohsiung J Med Sci. 2022;38(7):662-674.

[4] Chen LY, Zhi Z, Wang L, et al. NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling. J Pathol. 2019;248(1):103-115.

[5] D’Afonseca V, Gonzalez G, Salazar M, Arencibia AD. Computational analyses on genetic alterations in the NSD genes family and the implications for colorectal cancer development. Ecancermedicalscience. 2020;14:1001.

[6] Garcia-Carpizo V, Sarmentero J, Han B, et al. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation. Sci Rep. 2016;6:32952.

[7] He C, Liu C, Wang L, Sun Y, Jiang Y, Hao Y. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma. Cell Death Dis. 2019;10(2):65.

[8] Murali M, Saloura V. Understanding the roles of the NSD protein methyltransferases in head and neck squamous cell carcinoma. Genes (Basel). 2022;13(11).

[9] Sengupta D, Zeng L, Li Y, et al. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. Mol Cell. 2021;81(21):4481-4492 e4489.

[10] Want MY, Tsuji T, Singh PK, et al. WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer. 2021;9(2):e001374.

[11] Zhao LH, Li Q, Huang ZJ, et al. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer. Cell Death Dis. 2021;12(11):974.

[12] Evans DL, Zhang H, Ham H, et al. MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication. Cell Cycle. 2016;15(1):95-105.

[13] Toyokawa G, Cho HS, Masuda K, et al. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia. 2011;13(10):887-898.

[14] Yang P, Guo L, Duan ZJ, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012;32(15):3121-3131.

[15] Brito JL, Walker B, Jenner M, et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009;94(1):78-86.

[16] Song DLJ, Chen Y, Liu A, et al. NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein. Oncogene. 2021;40(16):2952-2967.

[17] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.

[18] Gupta S. Screening for colorectal cancer. Hematol Oncol Clin North Am. 2022;36(3):393-414.

[19] Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15(2):103-113.

[20] Parang B, Barrett CW, Williams CS. AOM/DSS model of colitis-associated cancer. Methods Mol Biol. 2016;1422:297-307.

[21] Schulz-Heddergott R, Stark N, Edmunds SJ, et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell. 2018;34(2):298-314 e297.

[22] Zhu L, Yu CL, Zheng Y. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-beta/TGF-betaRI/SMADs signaling. Biochem Biophys Res Commun. 2019;519(3):489-496.

[23] Chen J, Huang XF. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther. 2009;8(14):1313-1317.

[24] Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003;94(11):965-973.

[25] Wei J, Wei C, Wang M, et al. The GTPase-activating protein GIT2 protects against colitis by negatively regulating toll-like receptor signaling. Proc Natl Acad Sci USA. 2014;111(24):8883-8888.

[26] Moon SW, Son HJ, Mo HY, Choi EJ, Yoo NJ, Lee SH. Mutation and expression alterations of histone methylation-related NSD2, KDM2B and SETMAR genes in colon cancers. Pathol Res Pract. 2021;219:153354.

RIGHTS & PERMISSIONS

2024 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.